
Diego A. Díaz-García Highlighted the Results of SUPE_R Trial
Diego A. Díaz-García, Medical Oncologist, CEO, and Founder of CánCare – Advanced Oncology Specialty, shared a post on X about a paper by Kasper Guldbrandsen et al. published in the Journal of Thoracic Oncology:
“SUPE_R trial: In stage I–III NSCLC, [18F]FDG PET/CT vs ceCT after curative treatment showed:
- Same rate of recurrences treated curatively (48%)
- More detected via scheduled follow-up (90% vs 77%)
- No TTR or OS benefit
JTO & JTO CRR.”
Title: Surveillance With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of Patients With Stage I-to-III Lung Cancer After Completion of Curative treatment (SUPE_R): A Randomized Controlled Trial
Authors: Kasper Guldbrandsen, Martin Bloch, Kristin Skougaard, Lise Ahlborn, Erik Jakobsen, Anette Højsgaard, Rene Petersen, Lars Møller, Morten Dahl, Boe Sorensen, Malene Frank, Jeanette Ehlers, Martin Krakauer, Peter Gørtz, Elisabeth Albrecht-Beste, Julie Grüner, Zaigham Saghir, Joan Fledelius, Anne Nielsen, Paw Holdgaard, Søren Nielsen, Mette Pøhl, Svetlana Borissova, Lotte Land, Charlotte Kristiansen, Tine McCulloch, Lise Mortensen, Hanne Nellemann, Malene Christophersen, Ole Hilberg, Thor Rasmussen, Signe Schwaner, Christian Laursen, Uffe Bodtger, Liza Sopina, Markus Lonsdale, Christian Meyer, Oke Gerke, Jann Mortensen, Torben Rasmussen, Barbara Fischer.
You can read the Full Article on the Journal of Thoracic Oncology.
More posts featuring Diego A. Díaz-García on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023